Journal
FUTURE CARDIOLOGY
Volume 12, Issue 1, Pages 45-58Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fca.15.60
Keywords
acetylsalicylic acid; antiplatelet; cardiovascular disease; diabetes; Durlaza; extended-release; microcapsule; secondary prevention; thrombosis
Categories
Ask authors/readers for more resources
Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes systemic ASA absorption and provides sustained antiplatelet effects over a 24-h period.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available